Population pharmacokinetics and optimal design of paediatric studies for famciclovir

British Journal of Clinical Pharmacology

Volumn 68, Issue 4, 2009, Pages 546-560

  Ogungbenro, Kayode ^a   Matthews, Ivan ^b   Looby, Michael ^a   Kaiser, Guenther ^a   Graham, Gordon ^b   Aarons, Leon ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Famciclovir; Mixed effects modelling; Optimal design; Paediatric pharmacokinetics; Population pharmacokinetics

Indexed keywords

FAMCICLOVIR; PENCICLOVIR;

ADULT; ARTICLE; COMPARTMENT MODEL; CREATININE CLEARANCE; DRUG ABSORPTION; DRUG BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; SIMULATION;

2-AMINOPURINE; ADULT; AGE FACTORS; ANTIVIRAL AGENTS; AREA UNDER CURVE; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFANT; MALE; MODELS, BIOLOGICAL; RESEARCH DESIGN; TIME FACTORS;

EID: 70449133860     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2009.03479.x     Document Type: Article

References (35)

1. European Commission. Better Medicine for Children, Proposed Regulatory Actions on Paediatric Medicinal Products. Brussels : European Commission Brussels, 2002. Available at http://ec.europa.eu/enterprise/pharmaceuticals/ pharmacos/docs/doc2002/feb/cd-pediatrics-en.pdf (last accessed 12 March 2008).
2. European Medicines Agency. Clinical Investigation of Medicinal Products in the Paediatric Population. 2001. Available at http://www.emea.europa.eu/pdfs/ human/ich/271199en.pdf (last accessed 12 March 2008).
3. Anderson BJ, McKee AD, Holford NH. Size, myths and the clinical pharmacokinetics of analgesia in paediatric patients. Clin Pharmacokinet 1997 33 : 313 327.
4. Ginsberg G, Hattis D, Sonawane B, Russ A, Banati P, Kozlak M, Smolenski S, Goble R. Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. Toxicol Sci 2002 66 : 185 200.
5. Reed MD. Optimal sampling theory: an overview of its application to pharmacokinetic studies in infants and children. Pediatrics 1999 104 : 627 632.
6. Ritschel WA, Kearns GL. Handbook of Basic Pharmacokinetics. Washington, DC : American Pharmaceutical Association, 1998.
7. FDA. Guidance for Industry, General Consideration for Paediatric Pharmacokinetic Studies for Drugs and Biological Products. 1998. Available at http://www.fda.gov/cder/guidance/index.htm (last accessed 14 September 2006).
8. Novartis AG. Famvir® (famciclovir). 2006. Available at http://www.fda.gov/cder/foi/label/2006/020363s027s028lbl.pdf (last accessed 28 February 2008).
9. Gill KS, Wood MJ. The clinical pharmacokinetics of famciclovir. Clin Pharmacokinet 1996 31 : 1 8.
10. Filer CW, Allen GD, Brown TA, Fowles SE, Hollis FJ, Mort EE, Prince WT, Ramji JV. Metabolic and pharmacokinetic studies following oral administration of 14C-famciclovir to healthy subjects. Xenobiotica 1994 24 : 357 368.
11. Boike SC, Pue M, Audet PR, Freed MI, Fairless A, Ilson BE, Zariffa N, Jorkasky DK. Pharmacokinetics of famciclovir in subjects with chronic hepatic-disease. J Clin Pharmacol 1994 34 : 1199 1207.
12. Boike SC, Pue MA, Freed MI, Audet PR, Fairless A, Ilson BE, Zariffa N, Jorkasky DK. Pharmacokinetics of famciclovir in subjects with varying degrees of renal impairment. Clin Pharmacol Ther 1994 55 : 418 426.
13. Pue MA, Pratt SK, Fairless AJ, Fowles S, Laroche J, Georgiou P, Prince W. Linear pharmacokinetics of penciclovir following administration of single oral doses of Famciclovir 125, 250, 500 and 750 mg to healthy-volunteers. J Antimicrob Chemother 1994 33 : 119 127.
14. Rolan P. Pharmacokinetics of new antiherpetic agents. Clin Pharmacokinet 1995 29 : 333 340.
15. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976 16 : 31 41.
16. Beal SL, Sheiner LB. NONMEM Users Guides, Parts I-VII. NONMEM Project Group. San Francisco, CA : University of California, 1992.
17. Anderson BJ, Allegaert K, Holford NHG. Population clinical pharmacology of children: modelling covariate effects. Eur J Pediatr 2006 165 : 819 829. (Pubitemid 44627767)
18. Holford NH. A size standard for pharmacokinetics. Clin Pharmacokinet 1996 30 : 329 332.
19. West GB, Brown JH, Enquist BJ. A general model for the origin of allometric scaling laws in biology. Science 1997 276 : 122 126.
20. West GB, Brown JH, Enquist BJ. The fourth dimension of life: fractal geometry and allometric scaling of organisms. Science 1999 284 : 1677 1679.
21. Parke J, Holford NH, Charles BG. A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed 1999 59 : 19 29.
22. Holford N. Wings for NONMEM. 611. 2006. Available at http://wfn. sourceforge.net (last accessed 12 March 2008).
23. Cole TJ, Freeman JV, Preece MA. British 1990 growth reference centiles for weight, height, body mass index and head circumference fitted by maximum penalized likelihood. Stat Med 1998 17 : 407 429.
24. Savory DJ. Reference ranges for serum creatinine in infants, children and adolescents. Ann Clin Biochem 1990 27 : 99 101.
25. Schwartz GJ, Haycock GB, Spitzer A. Plasma creatinine and urea concentration in children: normal values for age and sex. J Pediatr 1976 88 : 828 830.
26. Atkinson AC, Donev AN. Optimum Experimental Designs. Oxford : Oxford University Press, 1992.
27. Gagnon R, Leonov S. Optimal population designs for PK models with serial sampling. J Biopharm Stat 2005 15 : 143 163.
28. Gueorguieva I, Ogungbenro K, Graham G, Glatt S, Aarons L. A program for individual and population optimal design for univariate and multivariate response pharmacokinetic- pharmacodynamic models. Comput Methods Programs Biomed 2007 86 : 51 61.
29. Retout S, Mentré F. Further developments of the Fisher information matrix in nonlinear mixed effects models with evaluation in population pharmacokinetics. J Biopharm Stat 2003 13 : 209 227.
30. Stein M. Large sample properties of simulations using latin hypercube sampling. Technometrics 1987 29 : 143 151.
31. Ogungbenro K, Graham G, Gueorguieva I, Aarons L. The use of a modified Fedorov exchange algorithm to optimise sampling times for population pharmacokinetic experiments. Comput Methods Programs Biomed 2005 80 : 115 125.
32. Ogungbenro K, Aarons L. An effective approach for obtaining optimal sampling windows for population pharmacokinetic experiments. J Biopharm Stat 2008 19 : 174 189.
33. Ogungbenro K, Aarons L. How many subjects are necessary for population pharmacokinetic experiments? Confidence interval approach. Eur J Clin Pharmacol 2008 64 : 705 713.
34. Ette EI, Onyiah LC. Estimating inestimable standard errors in population pharmacokinetic studies: the bootstrap with winsorization. Eur J Drug Metab Pharmacokinet 2002 27 : 213 224.
35. Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 2008 48 : 303 332.